Systemic anti-cancer therapy

The latest systematic anti-cancer therapies with highly trained 1-1 nursing and integrative cancer care

Overview

At GenesisCare, our medical oncology centres offer all available types of systemic anti-cancer therapies (SACTs). Our oncologists, nursing and pharmacy teams work closely together to ensure our patients have access to the latest treatments, safely and effectively.

Few private oncology providers offer such an extensive and professionally managed SACTs service offering a comprehensive range of:

  • Immunotherapy
  • Targeted therapies
  • Hormone therapies
  • Chemotherapy
  • Monoclonal antibodies

Expert teams

We have specialist cancer nurses and dedicated pharmacy teams.

  • UKONS SACT competency passport
  • Additional nursing qualifications, such as central venous access
  • 1-1 nursing with extensive experience in oncology care settings, including leading teaching hospitals
  • All medical oncology centres have experienced oncology and haematology pharmacists

Latest technologies

We use the latest technologies to improve efficiency and patient safety in SACT delivery.

  • Plum 360™ smart infusion pumps
  • ICU Medical MedNet ™ medicines safety platform
  • iQemo prescribing platform
  • Genetic and genomic testing

Our medical oncology centres

  • Bristol
  • Cambridge
  • Milton Keynes
  • Maidstone
  • Oxford
  • Windsor

All of these centres carry the Macmillan Quality Environment Mark (MQEM). Patients are treated in dedicated chemotherapy suites, with access to a 24/7 on-call service for emergency admissions.

Integrative cancer care

We embed integrative cancer care into our pathways to support patients throughout their treatment and beyond.

Refer a patient

To refer a patient for SACT or for more information about our services at GenesisCare please get in touch.
Make a referral

Expert teams

Specialist cancer nurses

Our cancer nurses are specialists in providing systemic anti-cancer therapies (SACTs), with extensive training and experience at leading cancer centres. They have the most up-to-date knowledge of the many types of cancer treatment, including how to administer them and manage side effects.

  • The Systemic Anti-Cancer Therapy (SACT) competency passport, a programme run by the UK Oncology Nursing Society (UKONs), showing that our nurses have the competence and knowledge to work in the most advanced SACTs centres.
  • Specialist training to ensure careful and accurate placement of cannulas and central venous access devices.
  • Active in addressing any patient concerns or symptoms, recognising problems quickly and referring to immediate care when needed.
  • Highly experienced with in-clinic procedures such as blood tests, blood transfusions, monitoring and assessing side effects.
  • Each nurse also has special training in connecting with and supporting people going through a life-changing experience like cancer.

Dedicated pharmacy teams

Our pharmacy teams in each centre are led by experienced oncology/haematology pharmacists that specialise in the wide range of systemic cancer treatment available. They are available onsite to provide expert pharmaceutical information’s to patients, consultants, and the nursing team.

Our team are members of British Oncology Pharmacy Association (BOPA) and complete the BOPA verification SACT Passport for pharmacy.

They ensure safe procurement of SACTs and that all pharmaceutical regulations are adhered to at all times, while ensuring safe prescribing of SACT medicines.

Latest technologies

We use the latest technologies to improve efficiency and patient safety in SACT delivery.

  • Plum 360 Smart Infusion System (from ICU Medical)
  • ICU Medical MedNet medicines safety software (from ICU Medical) with a full drug library created by GenesisCare utilizing the software
  • iQemo electronic chemotherapy prescribing system (from iQHealthTech)

With a three-way partnership between GenesisCare, ICU Medical and iQHealthTech, we have been able to implement Bar Code Medication Administration (BCMA). This ground-breaking innovation allows our chemotherapy nurses to:

  • Identify the patient using a barcoded patient ID wristband
  • Associate the infusion pump to the patients iQemo prescription
  • Check and capture the medication details via a barcoded label

These features greatly improve safety and give a complete and detailed administration record by sending all details, including start and stop times, to the patient’s record in iQemo.

 

BCMA verification reduces the possibility of a potential error and will improve efficiency of medication delivery. Patient safety is extremely important to GenesisCare and we will do whatever we can to ensure the safe provision and administration of chemotherapy medicines. Titilayo Alagbe, GenesisCare Head of Pharmacy

The key benefits of these technologies working together means:

  • Greater patient safety
  • Reduced chair time for patients
  • Greater workflow and operational efficiencies such as reduced nursing time in documenting administration details
  • Improved data quality
  • Reduced costs of consumables
  • Reduced drug wastage
  • Reduced risk of vein pain on drug delivery for patients
To know that extra safety measures are in place to prevent human error from occurring makes me feel very safe. Patient at GenesisCare

Integrative cancer care

We embed integrative cancer care into our pathways to support patients throughout their treatment and beyond. We provide a comprehensive, consultant-led package of evidence-based therapies that have been proven to alleviate cancer-related concerns and improve treatment outcomes. These therapies include exercise medicine from our qualified physiotherapists, and counselling, massage, acupuncture and reflexology through our partnership with the charity, Penny Brohn UK. This is at no extra cost to our patients or their insurers.

All our medical oncology centres have also received the Macmillan Quality Environment Mark which is awarded to cancer environments that go above and beyond to create welcoming and friendly spaces for people living with cancer.